Depression Clinical Trial
Official title:
Examining the Feasibility of a Mobile Mental Health Application (Rose) for Augmentation of In-person Psychotherapy
Verified date | December 2019 |
Source | Ask Rose |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
There is an urgent need to better understand and manage the mental health burden among
working adults. Up to 40% of persons with serious mental illnesses do not receive care or
stop intervention programs due to negative stigma. Additionally, nearly 50 percent of
respondents diagnosed with an anxiety disorder said it interfered with their relationships
with coworkers. Close to $6000 USD is lost per working person each year due to depression and
its effects.
Rose (Recognition of Speech and Emotion) is a mental health-focused application that utilizes
artificial intelligence to identify symptoms and provides targeted, tailored in-person
therapy solutions for its users. The RoSE application provides solutions to supplement
ongoing in-person psychotherapy. This includes journaling and daily assessments that provide
curated content and feedback. The current feasibility study aims to recruit 45 established
outpatients with at least mild depressive and/or anxiety symptoms who will be consented and
enrolled in a five to ten-week study. There are two study arms: (1) the intervention arm and
(2) a waitlist control arm. During the course of the study, the participants in the
intervention arm will use the RoSE application daily. They will receive either weekly
in-person psychotherapy with their established psychotherapist for a total of four sessions
over four weeks or biweekly in-person psychotherapy with their established psychotherapist
for a total of four sessions over eight weeks. The participants in the waitlist arm will
serve as controls unless there is attrition from the intervention group at which time
waitlist participants will be offered a spot in the intervention arm. The primary objectives
of the study are (1) To assess the usability of the RoSE application and (2) To evaluate the
short-term impact on mood and anxiety of using the RoSE application to augment in-person
psychotherapy. The secondary objectives are (1) To examine the usage and utility of an
in-application journaling function and (2) To examine the usage and utility of in-application
curated insights.
Status | Active, not recruiting |
Enrollment | 45 |
Est. completion date | December 27, 2019 |
Est. primary completion date | November 29, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - English speaking; ->=18 years of age; - Score >5 on PHQ-9 and/or >5 on GAD-7; - Have an accessible smartphone with a data plan; - Ability to dedicate one hour a week for therapy sessions; - Ability to give informed consent and understand the tasks involved. Exclusion Criteria: - Current psychosis (e.g., hallucinations, delusions, thought disorder); - Current suicidal ideation or homicidal ideation |
Country | Name | City | State |
---|---|---|---|
United States | Key Point Health Services | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Ask Rose |
United States,
Economides M, Ranta K, Nazander A, Hilgert O, Goldin PR, Raevuori A, Forman-Hoffman V. Long-Term Outcomes of a Therapist-Supported, Smartphone-Based Intervention for Elevated Symptoms of Depression and Anxiety: Quasiexperimental, Pre-Postintervention Study. JMIR Mhealth Uhealth. 2019 Aug 26;7(8):e14284. doi: 10.2196/14284. — View Citation
Giosan C, Cobeanu O, Mogoase C, Szentagotai A, Muresan V, Boian R. Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial. Trials. 2017 May 12;18(1):215. doi: 10.1186/s13063-017-1960-1. — View Citation
Goldin PR, Lindholm R, Ranta K, Hilgert O, Helteenvuori T, Raevuori A. Feasibility of a Therapist-Supported, Mobile Phone-Delivered Online Intervention for Depression: Longitudinal Observational Study. JMIR Form Res. 2019 Jan 22;3(1):e11509. doi: 10.2196/ — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average weekly completion rate for Mood check-in | Over the study period, the mobile app will collect time (date/time) the user fills in the Mood Likert Scale. We will calculate the average number of times the user fills in the scale each week. | 4 weeks | |
Primary | Average weekly completion rate for Anxiety check-in | Over the study period, the mobile app will collect time (date/time) the user fills in the Anxiety Likert Scale. We will calculate the average number of times the user fills in the scale each week. | 4 weeks | |
Primary | Average weekly completion rate for online journaling | Over the study period, the mobile app will collect time (date/time) the user fills the online journal. We will calculate the average number of times the user fills in the scale each week. | 4 weeks | |
Primary | Adherence to Patient Health Questionnaire-9 (PHQ-9) survey completion at Baseline | Over the study period, the mobile app will prompt the user to fill in the PHQ-9 survey. The app will collect time (date/time) the user fills this in. We will record the level of adherence: Full ( Baseline filled) vs. Partial (Baseline not filled) | Baseline | |
Primary | Adherence to Patient Health Questionnaire-9 (PHQ-9) survey completion at Week 2 | Over the study period, the mobile app will prompt the user to fill in the PHQ-9 survey. The app will collect time (date/time) the user fills this in. We will record the level of adherence: Full ( Week 2 filled) vs. Partial (Week 2 not filled) | Week 2 | |
Primary | Adherence to General Anxiety Disorder-7 (GAD-7) survey completion at Week 4 | Over the study period, the mobile app will prompt the user to fill in the PHQ-9 survey. The app will collect time (date/time) the user fills this in. We will record the level of adherence: Full ( Week 4 filled) vs. Partial (Week 4 not filled) | Week 4 | |
Primary | Adherence to General Anxiety Disorder-7 (GAD-7) survey completion at Baseline | Over the study period, the mobile app will prompt the user to fill in the GAD-7 survey. The app will collect time (date/time) the user fills this in. We will record the level of adherence: Full ( Baseline filled) vs. Partial (Baseline not filled) | Baseline | |
Primary | Adherence to General Anxiety Disorder-7 (GAD-7) survey completion at Week 2 | Over the study period, the mobile app will prompt the user to fill in the GAD-7 survey. The app will collect time (date/time) the user fills this in. We will record the level of adherence: Full ( Week 2 filled) vs. Partial (Week 2 not filled) | Week 2 | |
Primary | Adherence to General Anxiety Disorder-7 (GAD-7) survey completion at Week 4 | Over the study period, the mobile app will prompt the user to fill in the GAD-7 survey. The app will collect time (date/time) the user fills this in. We will record the level of adherence: Full ( Week 4 filled) vs. Partial (Week 4 not filled) | Week 4 | |
Primary | Assess objective and subjective quality of mobile app used | At the end of the study (week 5), participants will be asked to complete the Mobile Application Rating Scale (MARS) to score the intervention app on the criteria of engagement, functionality, aesthetics, and information quality, as well as app subjective quality. Each MARS item used a 5-point scale (1-Inadequate, 2-Poor, 3-Acceptable, 4-Good, 5-Excellent). The MARS is calculated as mean scores of the engagement, functionality, aesthetics, and information quality objective sub-scales, and an overall mean app quality total score. | Week 5 | |
Secondary | Change in Short term impact on anxiety as assessed by the GAD-7 | The GAD-7 is a self-administered 7 item instrument that uses some of the DSM-V criteria for anxiety to identify probable cases of GAD along with measuring anxiety symptom severity. Responders are asked to rate the frequency of anxiety symptoms in the last 2 weeks on a Likert scale ranging from 0-3. Severity can be determined by examining the total score. A meaningful change is 5 or more points. | Baseline, 4 weeks | |
Secondary | Change in Short term impact on anxiety as assessed by the PHQ-9 | The PHQ-9 is a self-administered 9 item instrument that uses some of the DSM-V diagnostic symptom criteria that define DSM-IV Major Depressive Disorder. Responders are asked to rate the frequency of depressive symptoms in the last 2 weeks on a Likert scale ranging from 0-3. Severity can be determined by examining the total score. A meaningful change is 5 or more points. | Baseline, 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |